Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition Life Science Investing
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco Life Science Investing
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 Life Science Investing
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 Life Science Investing
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4R? Bispecific Antibody ATI-052 Supporting Expedited Clinical Development Life Science Investing
Biologics License Application for Subcutaneous Formulation of "LEQEMBI®" for the Treatment of Early Alzheimer's Disease Accepted in China Life Science Investing
